Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of analyst coverage. GLP-1 adoption has fueled Lilly’s differentiated growth profile, but additional growth drivers could add momentum, the analyst tells investors in a research note. The firm expects label expansion of tirzepatide beyond diabetes and obesity to sleep apnea and heart failure in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Novo Nordisk’s (NYSE:NVO) GLP-1 Drugs Could Help Fight Alzheimer’s Disease
- Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
- Eli Lilly announces MHRA grants marketing authorization for donanemab
- GE Aerospace, GM report quarterly earnings beats: Morning Buzz
- Pfizer, Lilly pressed about telehealth prescriber relationships, STAT reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
